Pharma and BioTech Daily

Pharma and BioTech Daily

Pharma and BioTech News
Country USA
Language EN-US
Episodes 63
Latest 18.11.2026

Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what's important in pharma and biotech. Each weekday it condenses key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences. The show is produced by OWITH.ai, a boutique AI & data studio.

Episodes

  • FDA nods GSK's Nelkarmi, Isomorphic raises record 5B dollars | Pharma and Biotech Daily
    FDA nods GSK's Nelkarmi, Isomorphic raises record 5B dollars | Pharma and Biotech Daily 18.11.2026 4m
    GSK wins accelerated FDA approval for Nelkarmi in previously treated ALK positive lung cancer, and Isomorphic Labs raises a record 5 billion dollar Series C. Also: Lilly's oncology pact with Stipple Bio worth up to 5.9 billion dollars and a split Phase 3 result for AriBio's AR1001 in Alzheimer's disease. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Wednesday, November 18. Today, GSK wins an early FDA nod for its new lung cancer drug, a...
  • J&J buys Ollin for $2.2B, FDA approves Roche's giredestrant | Pharma and Biotech Daily
    J&J buys Ollin for $2.2B, FDA approves Roche's giredestrant | Pharma and Biotech Daily 17.11.2026 6m
    Johnson & Johnson pays $2.2 billion upfront for Ollin Biosciences and its Vabysmo challenger OLN324, and the FDA approves Genentech's Wilserdly (giredestrant) for ESR1 mutated breast cancer. Also: Helus Pharma's Phase 3 depression win, Lilly's purchase of Calytrix Bio, Seawolf's Sanofi pact and Novartis' ADC deal with OBI Pharma. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Tuesday, November 17. Today, Johnson and Johnson pays two ...
  • FDA rejects Summit's ivonescimab, EU backs AstraZeneca Baxfendy | Pharma and Biotech Daily
    FDA rejects Summit's ivonescimab, EU backs AstraZeneca Baxfendy | Pharma and Biotech Daily 16.11.2026 5m
    The FDA has rejected Summit and Akeso's lung cancer antibody ivonescimab over a missing overall survival win, while Europe's CHMP backed AstraZeneca's blood pressure drug Baxfendy and two China origin lung cancer medicines. We also cover Zevra's upheld refusal in Europe and Cellectis' deep job cuts as it pivots to in vivo gene editing. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Monday, November 16. Since Friday, the FDA has turned do...
  • Pfizer Blackstone 1.5B obesity deal, FDA vouchers shelved | Pharma and Biotech Daily
    Pfizer Blackstone 1.5B obesity deal, FDA vouchers shelved | Pharma and Biotech Daily 13.11.2026 5m
    Blackstone commits up to 1.5 billion dollars to Pfizer's monthly obesity shot berobenatide, and Reuters reports the FDA has shelved its Commissioner's National Priority Voucher program. Also: FDA staffing gaps, a Bristol Myers Squibb R&D overhaul, Windward Bio's 175 million dollar IPO and a 105 million dollar Series B for Neurosterix. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Friday, November 13. Today, private equity puts up se...
  • FDA GLP-1 Vision Warning, Compass Psilocybin NDA | Pharma and Biotech Daily
    FDA GLP-1 Vision Warning, Compass Psilocybin NDA | Pharma and Biotech Daily 12.11.2026 5m
    The FDA adds a possible NAION vision loss risk to the labels of all GLP-1 drugs, and Compass Pathways completes its psilocybin application for treatment resistant depression. Plus AstraZeneca buys Omniose, Abeona licenses a Phase three ready esophagitis drug, Valo and Montai merge, and Zura Bio drops a Phase two program. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Thursday, November 12. Today, the FDA adds a vision warning to every GL...
  • Beam Base Editing Sickle Cell Win, FDA Approves Pimjetmi | Pharma and Biotech Daily
    Beam Base Editing Sickle Cell Win, FDA Approves Pimjetmi | Pharma and Biotech Daily 11.11.2026 5m
    Beam Therapeutics' base editing therapy risto-cel meets its primary endpoint in the pivotal BEACON sickle cell study, and the FDA approves Pimjetmi, pimicotinib, from Abbisko and Merck KGaA for tenosynovial giant cell tumor. Also: BIO's BioAdvance plan to keep the US ahead of China in biotech, Gossamer Bio prepares a seralutinib launch after its first NDA, and the FDA clears Metagenomi's MGX-001 gene insertion trial in hemophilia A. Good morning from Pharma and Biotech Daily, the briefing on...
  • Vir Hepatitis Delta Phase 3 Win, argenx $1.15B Peptide Deal | Pharma and Biotech Daily
    Vir Hepatitis Delta Phase 3 Win, argenx $1.15B Peptide Deal | Pharma and Biotech Daily 10.11.2026 5m
    Vir Biotechnology reports a pivotal Phase 3 win in chronic hepatitis delta, and argenx agrees to buy Unnatural Products for up to 1.15 billion dollars to add oral macrocyclic peptides. Also: TG Therapeutics raises Briumvi guidance, Xenon's azetukalner filing and X-NOVA2 timing, and Atea's path to a hepatitis C filing. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Tuesday, November 10. Vir Biotechnology has a pivotal win in hepatitis del...
  • Lp(a)HORIZON Fails at AHA, FDA's Big November | Pharma and Biotech Daily
    Lp(a)HORIZON Fails at AHA, FDA's Big November | Pharma and Biotech Daily 09.11.2026 5m
    Full Lp(a)HORIZON results at AHA show Novartis' pelacarsen cut Lp(a) by 78 percent with no cardiovascular benefit, as the FDA heads into a crowded month of decisions on ivonescimab, deramiocel and povetacicept. Also: Mineralys' lorundrostat holds its effect at 48 weeks, Sarepta's new CEO faces falling Elevidys sales, and Moderna raises guidance. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Monday, November 9. Since Friday, a large outc...
  • Zealand Pharma & Generate Biomedicines' $1.2B AI Deal | Pharma and Biotech Daily
    Zealand Pharma & Generate Biomedicines' $1.2B AI Deal | Pharma and Biotech Daily 15.10.2026 5m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of exciting advancements and strategic shifts reshaping the landscape of drug development and patient care. A noteworthy collaboration between Zealand Pharma and Generate:Biomedicines is leading the charge, aiming to revolutionize treatment for obesity and metabolic diseases. This strategic partnership, valued at a potential $1.2 b...
  • GSK Invests $800M in Biologics Facility | Pharma and Biotech Daily
    GSK Invests $800M in Biologics Facility | Pharma and Biotech Daily 14.10.2026 5m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories shaping the industry. Let's begin with GSK's bold move to expand its biologics capabilities. The company has announced an $800 million investment in a new biologics production facility and innovation hub in Pennsylvania. This state-of-the-art facility aims to address the increasing demand for biologic...
  • Asahi Kasei's $920M AiCuris Buy Leads to FDA OK | Pharma and Biotech Daily
    Asahi Kasei's $920M AiCuris Buy Leads to FDA OK | Pharma and Biotech Daily 13.10.2026 4m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling stories that highlight the dynamic nature of the industry, marked by strategic acquisitions, groundbreaking research, and significant regulatory milestones. Starting with Asahi Kasei's acquisition of Bayer spinout AiCuris for a substantial $920 million, this investment has culminated in the FDA approval of a novel her...
  • GSK AI Partnership & Roche's FDA Win: $117M IPO Buzz | Pharma and Biotech Daily
    GSK AI Partnership & Roche's FDA Win: $117M IPO Buzz | Pharma and Biotech Daily 12.10.2026 4m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts shaping the industry landscape. We begin with the integration of artificial intelligence into drug discovery. GSK's recent collaboration with Chai Discovery exemplifies the growing trend of using AI to transform research and development processes. By integrating AI into its drug ...
  • Novartis' Rhapsido FDA Expansion Boosts Revenue Potential | Pharma and Biotech Daily
    Novartis' Rhapsido FDA Expansion Boosts Revenue Potential | Pharma and Biotech Daily 09.10.2026 4m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant advancements and challenges shaping these dynamic sectors. In a notable regulatory update, the U.S. Food and Drug Administration has expanded the label for Novartis' Rhapsido to include symptomatic dermographism, based on compelling Phase 3 clinical trial data. Rhapsido, a small-molecule Bruton’s tyrosine kinase...
  • Cerevance's Solengepras Hits Phase 3 Success for Parkinson's | Pharma and Biotech Daily
    Cerevance's Solengepras Hits Phase 3 Success for Parkinson's | Pharma and Biotech Daily 08.10.2026 4m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful advancements and strategic shifts shaping the industry landscape. Cerevance has made headlines with its drug Solengepras achieving a major milestone in a Phase 3 trial for Parkinson's disease. The drug significantly reduced "off" time, those challenging periods when symptoms resurface as medication effects diminish...
  • Shionogi Acquires Intrabio for $2B: Rare Disease Focus | Pharma and Biotech Daily
    Shionogi Acquires Intrabio for $2B: Rare Disease Focus | Pharma and Biotech Daily 07.10.2026 4m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical industry is no stranger to dynamic growth, as evidenced by Shionogi's recent acquisition of Intrabio for a staggering $2 billion. This move is more than just a financial transaction; it represents a strategic pivot towards addressing rare diseases. Through this acquisition, Shionogi gains access to Aqneursa, a drug approved for tackling two i...
  • Bayer's $2.2B Ohio Site Boosts U.S. Pharma | Pharma and Biotech Daily
    Bayer's $2.2B Ohio Site Boosts U.S. Pharma | Pharma and Biotech Daily 06.10.2026 5m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of groundbreaking advancements and strategic shifts that are defining the industry's path forward. Bayer has made headlines with its strategic $2.2 billion investment in a new Ohio manufacturing site. This move highlights the critical importance of strengthening domestic manufacturing capabilities, especially within the context...
  • Novartis's $7.8B mRNA Deal with Abogen | Pharma and Biotech Daily
    Novartis's $7.8B mRNA Deal with Abogen | Pharma and Biotech Daily 05.10.2026 5m
    Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the rapidly evolving landscape of drug development, where groundbreaking scientific advances and strategic corporate maneuvers are reshaping patient care and industry standards. The integration of artificial intelligence in drug discovery is gaining momentum, with companies like Xaira Therapeutics leading the way. By leveraging AI to enhanc...
  • Sanofi's $1B Deal with Regeneron: Immunology Breakthroughs | Pharma and Biotech Daily
    Sanofi's $1B Deal with Regeneron: Immunology Breakthroughs | Pharma and Biotech Daily 02.10.2026 4m
    Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape is constantly evolving, with innovative partnerships, groundbreaking clinical trial results, and regulatory shifts shaping the future of healthcare. Today, we delve into these key areas, highlighting significant industry movements and their potential impacts on patient care. Sanofi's renewed collaboration with Regeneron marks a pivotal strategic m...
  • Eli Lilly's Retatrutide: 25% Weight Loss in Phase 3 Trial! | Pharma and Biotech Daily
    Eli Lilly's Retatrutide: 25% Weight Loss in Phase 3 Trial! | Pharma and Biotech Daily 01.10.2026 5m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in...
  • AstraZeneca's $2B Oncology Investment | Pharma and Biotech Daily
    AstraZeneca's $2B Oncology Investment | Pharma and Biotech Daily 30.09.2026 5m
    Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative developments across the pharmaceutical and biotech sectors, highlighting strategic investments, innovative therapies, and regulatory milestones. AstraZeneca's recent $2 billion investment in Summit Therapeutics is a testament to the industry's focus on cutting-edge oncology solutions. This substantial funding aim...

Popular in

The podcast also appears in the podcast charts of these countries.